The Dynamics of Interleukin-10-Afforded Protection during Dextran Sulfate Sodium-Induced Colitis by Cardoso, Ana et al.
March 2018 | Volume 9 | Article 4001
Original research
published: 01 March 2018
doi: 10.3389/fimmu.2018.00400
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Massimo Gadina, 
National Institute of Arthritis and 
Musculoskeletal and Skin Diseases, 
United States
Reviewed by: 
Robson Coutinho-Silva, 
Universidade Federal do Rio de 
Janeiro, Brazil  
Cinzia Fionda, 
Sapienza Università di Roma, Italy
*Correspondence:
Margarida Saraiva  
margarida.saraiva@ibmc.up.pt
†Present address: 
Guilhermina M. Carriche, 
Institute of Infection Immunology, 
TWINCORE, Centre for Experimental 
and Clinical Infection Research, a 
Joint Venture between the Medical 
School Hannover (MHH) and the 
Helmholtz Centre for Infection 
Research (HZI), Hannover, Germany; 
Valentine Murigneux, 
UQ Diamantina Institute, Translational 
Research Institute, University of 
Queensland, Brisbane, 
QLD, Australia
‡These authors have contributed 
equally for this work.
§Co-senior authors.
Specialty section: 
This article was submitted to 
Inflammation, 
a section of the journal 
Frontiers in Immunology
Received: 11 August 2017
Accepted: 13 February 2018
Published: 01 March 2018
Citation: 
Cardoso A, Gil Castro A, Martins AC, 
Carriche GM, Murigneux V, Castro I, 
Cumano A, Vieira P and Saraiva M 
(2018) The Dynamics of Interleukin-
10-Afforded Protection 
during Dextran Sulfate 
Sodium-Induced Colitis. 
Front. Immunol. 9:400. 
doi: 10.3389/fimmu.2018.00400
The Dynamics of interleukin-10-
afforded Protection during Dextran 
sulfate sodium-induced colitis
Ana Cardoso1,2,3,4,5,6,7, Antonio Gil Castro6,7‡, Ana Catarina Martins1,2‡,  
Guilhermina M. Carriche1,2†, Valentine Murigneux8,9†, Isabel Castro6,7, Ana Cumano3,4,5, 
Paulo Vieira3,4,5§ and Margarida Saraiva1,2*§
1 i3S – Instituto de Investigação e Inovação em Saúde, Porto, Portugal, 2 IBMC – Instituto de Biologia Molecular e Celular, 
Universidade do Porto, Porto, Portugal, 3 Department of Immunology, Unité Lymphopoièse, Institut Pasteur, Paris, France, 
4 University Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, France, 5 INSERM U1223, Paris, France, 6 ICVS, 
University of Minho, Braga, Portugal, 7 ICVS/3B’s – PT Government Associate Laboratory, Braga, Portugal, 8 Department of 
Immunology, Unité Intégrité du génome, immunité et cancer, Institut Pasteur, Paris, France, 9 Department of Genomes and 
Genetics, Unité Intégrité du génome, immunité et cancer, Institut Pasteur, Paris, France
Inflammatory bowel disease encompasses a group of chronic-inflammatory conditions 
of the colon and small intestine. These conditions are characterized by exacerbated 
inflammation of the organ that greatly affects the quality of life of patients. Molecular 
mechanisms counteracting this hyperinflammatory status of the gut offer strategies for 
therapeutic intervention. Among these regulatory molecules is the anti-inflammatory 
cytokine interleukin (IL)-10, as shown in mice and humans. Indeed, IL-10 signaling, 
particularly in macrophages, is essential for intestinal homeostasis. We sought to 
investigate the temporal profile of IL-10-mediated protection during chemical colitis and 
which were the underlying mechanisms. Using a novel mouse model of inducible IL-10 
overexpression (pMT-10), described here, we show that mice preconditioned with IL-10 
for 8 days before dextran sulfate sodium (DSS) administration developed a milder colitic 
phenotype. In IL-10-induced colitic mice, Ly6C cells isolated from the lamina propria 
showed a decreased inflammatory profile. Because our mouse model leads to transcrip-
tion of the IL-10 transgene in the bone marrow and elevated seric IL-10 concentration, 
we investigated whether IL-10 could imprint immune cells in a long-lasting way, thus 
conferring sustained protection to colitis. We show that this was not the case, as IL-10-
afforded protection was only observed if IL-10 induction immediately preceded DSS-
mediated colitis. Thus, despite the protection afforded by IL-10 in colitis, novel strategies 
are required, specifically to achieve long-lasting protection.
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inTrODUcTiOn
Inflammatory bowel disease (IBD) comprises a complex group of inflammatory conditions of the 
gastrointestinal tract (1) affecting an increasing number of patients worldwide (2–4). Both forms 
of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), result from alterations in the immune 
homeostasis of the intestinal tissue leading to local uncontrolled inflammation (5, 6). The gut is a 
very particular site in terms of immune repertoire and regulation, as even in homeostatic conditions 
constant exposure to antigens occurs (7). Thus, the maintenance of intestinal homeostasis, primarily 
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carried out by intestinal macrophages, requires a constant and 
fine-tuned balance between the state of tolerance and inflam-
mation (8). In the gut environment, macrophages encounter a 
plethora of stimuli, from dietary antigens to commensal bacteria, 
yet, due to their unique tissue-specific characteristics, remain 
tolerant (9). In the predisease stage, the epithelial or mucosal 
barriers become compromised allowing bacteria from the lumi-
nal side to invade the lamina propria of the gut (10). This event 
triggers an acute inflammatory response due to the activation of 
immune cells by direct contact with bacterial products (10). The 
induced inflammation results either in elimination of the foreign 
bacterial incursion or in an exacerbated immune response that 
can result in tissue damage. The damage caused by deregulated 
inflammation will perpetuate the activation of effector cells and 
ultimately lead to the clinical onset of IBD (10, 11).
Epidemiological studies have shown that the etiology of IBD 
is multifactorial, with genetic predisposition, dysfunctional intes-
tinal barrier and imbalances of the microbiome all contributing 
to this condition (12–15). Genome-wide association studies 
revealed that the main genetic alterations associated with IBD 
are found in genes encoding proteins linked to innate or adap-
tive immunity, such as the nucleotide-binding oligomerization 
domain-containing protein 2, Janus kinase (JAK) 2, and tumor 
necrosis factor superfamily 15 (16–18). Other alterations are 
associated with molecules involved in leukocyte trafficking, 
regulation of barrier function and secretion of defensins (17). 
Two reports associate loss-of-function mutations in interleukin 
(IL)-10 or IL-10R subunits with severe IBD (19, 20). These muta-
tions result in severe enterocolitis, with onset before one year of 
age, and unresponsiveness to immunosuppressive therapies. The 
only available therapy for these patients is immune reconstitu-
tion with hematopoietic stem cells (21–23). Although complete 
loss-of-function mutations in IL-10 and IL-10R strongly correlate 
with IBD, they have an extremely low occurrence rate (19, 24). 
The most frequent mutations affecting the IL-10 genes associated 
with IBD are in fact single-nucleotide polymorphisms associated 
with low expression of this molecule (25). However, harboring 
such mutations does not always translate in low serum levels 
of IL-10 (23) during the disease stage. This is likely due to the 
significant increase on the number of IL-10-producing myeloid 
cells in CD patients (26–29), to the extent that elevated serum 
levels of IL-10 correlate with disease activity in CD (30–32).
The role of IL-10 in intestinal inflammation is also seen in 
the mouse model, as IL-10-deficient mice develop microbiome-
dependent spontaneous enterocolitis (33). Furthermore, mice 
with macrophage restricted IL-10R deficiency also develop a 
spontaneous colitic profile (34), stressing the critical role of the 
monocyte/macrophage axis in the immunologic events leading to 
IBD. Interestingly, it has been shown, in a model of infection that 
IL-10 can exert a direct effect on monocytes/macrophages subsets, 
leading to changes in their inflammatory profile and survival (35). 
Moreover, IL-10 has been shown to confer protection from hyper-
inflammatory states by the induction of the JAK1/STAT3 signaling 
pathway that suppresses expression of proinflammatory mediators 
and activates expression of anti-inflammatory genes (36).
Taking into account the results obtained in murine models 
of IL-10 perturbation, the genetic correlation established in 
humans, and the anti-inflammatory properties of IL-10, this 
cytokine emerged as a very promising candidate for IBD therapy. 
However, in IBD patients IL-10-based therapy has not resulted in 
substantial clinical improvements (37). The main caveats in these 
clinical trials were the subcutaneous route of administration 
and the concentration of the recombinant molecule that did not 
ensure that IL-10 levels reached the mucosal sites, pointing out 
the importance of novel-locally targeted therapeutic strategies. 
Furthermore, IL-10 administration to IL-10-deficient murine 
models only protected from colitis if administered before disease 
establishment (38).
In this study, we report a novel mouse model of IL-10 over-
expression (the pMT-10 mouse) and use it to better explore 
the mechanisms of immune regulation elicited by IL-10 in the 
context of intestinal inflammation. We show that a short period of 
IL-10 overexpression prior to the induction of colitis ameliorates 
the disease outcome, despite the presence of CD11b+ Ly6C+ 
cells in the gut, previously associated with the development of 
detrimental inflammation. As compared to control animals that 
do not overexpress IL-10, Ly6C cells isolated from the gut lamina 
propria of colitic pMT-10 mice showed a decreased inflammatory 
profile. Thus, we propose that IL-10 overexpression impaired the 
response of these cells to the stimulus. In addition to the local 
effect of IL-10 in controlling exacerbated immune responses, our 
model allows for the study of IL-10 in imprinting de novo gener-
ated and circulating monocytes. This is because, constant IL-10 
expression is found in specific tissues, in pMT-10 mice, culminat-
ing in a systemic effect. Therefore, IL-10 is likely to affect other 
important compartments, such as the bone marrow (BM) and 
spleen. IL-10-afforded protection was only seen if IL-10 trigger-
ing immediately preceded dextran sulfate sodium (DSS)-induced 
colitis, thus calling for novel strategies that sustain the effect of 
IL-10 to offer long-lasting protection.
MaTerials anD MeThODs
ethics statement
In Portugal, all animal experiments were performed in strict 
accordance with recommendations of the European Union 
Directive 2010/63/EU and previously approved by Portuguese 
National Authority for Animal Health–Direção Geral de 
Alimentação e Veterinária (DGAV). Mice were euthanized by 
CO2 inhalation with efforts to minimize suffering.
In France, all animal procedures were approved by the Pasteur 
Institute Safety Committee and conducted according to French 
and European Community Institutional guidelines.
animals
The study involved the use of the following 7–14-week-old female 
mice: wild-type C57BL/6j, pMT-10-IL-10 inducible mice, and 
pMT-10 crossed with IL-10Rα-deficient mice (39) (pMT-10.
IL-10Rα−/−). Food was ad libitum for all animals.
generation of pMT-10 Mice
pMT10 mice were generated by A. Gil Castro and Paulo Vieira. 
Mouse IL-10 cDNA was cloned into the p169ZT vector, which 
FigUre 1 | A novel mouse model for inducible interleukin (IL)-10 expression: pMT-10 mice. (a) Schematic representation showing the targeting vector and insertion 
site. (B) Kinetics of IL-10 overexpression in the serum at different time points post Zn administration and Zn withdrawal. pMT-10 mice were fed with normal 
(pMT-10-Zn) or Zn-enriched (pMT-10 + Zn) water and at the indicated time points blood was harvested and the amount of IL-10 in serum measured by 
immunoassay. (c) qRT-PCR identified CD45− TER119− cell subsets from skin, bone marrow, and small intestine (SI) as the main producers of IL-10 in pMT-10 mice 
fed for 8 days with Zn-enriched water. In both (B,c), each point or bar represents the mean ± SEM for three independent mice. Data were analyzed with  
(B) two-way analysis of variance (Sidak’s multiple comparisons test) or (c) Student’s t-test, *p < 0.05; **p < 0.01; ***p < 0.001.
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carries a sheep metalloprotein (MT) 1a promoter, a β-globin 
splice site and a SV40 polyadenylation (polyA) signal. The result-
ing vector—pMT-10 (see Figure  1A)—was then injected into 
C57BL/6j eggs and transgenic founders were identified by PCR 
using MT and IL-10-specific primers. IL-10 overexpression was 
induced by feeding the mice a 2% sucrose solution with 50 mM 
of zinc (Zn) sulfate.
Dss-induced colitis
Mice were fed for 8 days with 3% DSS (TdB consultancy) in the 
drinking water, and were monitored, daily, for weight loss and 
disease progression. Colitis progression was measured by the 
Disease Activity Index (DAI), as previously described [Table 1 
(40)].
assessment of intestinal inflammation
Mice were euthanized on day 8 post-DSS administration or 
earlier if the symptoms of clinical disease (significant weight 
loss or diarrhea) became apparent. Samples from colons were 
immediately fixed in 4% paraformaldehyde. Then, 5 µm paraffin-
embedded sections were stained with hematoxylin and eosin, and 
inflammation was assessed in a blinded fashion using a previously 
described system [Table 2 (41)]. Samples were graded semiquan-
titatively from 0 to 3 for the four following criteria: (i) degree 
of epithelial hyperplasia and goblet depletion; (ii) leukocyte 
infiltration in the lamina propria; (iii) area of tissue affected; and 
(iv) the presence of markers of severe inflammation such as crypt 
abscesses submucosal inflammation and ulcers. For each sample, 
criteria scores were added to give an overall inflammation score 
of 0–12.
cytokine Quantification
Interleukin-10 concentration in the serum was quantified using a 
commercially available ELISA kit (R&D systems).
Preparation of cell suspensions
Isolation of non-hematopoietic cells (CD45− TER119−) or hemat-
opoietic (CD45+) BM cells followed standard protocols. Briefly, 
hematopoietic BM  cells were extracted by flushing the femurs 
and tibias with 2  mL of HBBS repeatedly. To obtain the BM 
non-hematopoietic cells, the bone fragments were incubated in 
RPMI medium with Liberase TL (0.5 mg/ml; Roche) for 30 min 
at 37°C. To help dissociation of non-hematopoietic cells from the 
bone, after each incubation period, the femurs and tibias were 
flushed with RPMI. We repeated this step three times after which 
we flushed the bones one last time, harvested the cell suspen-
sions and added 1 volume of RPMI containing 10% FCS. Small 
intestine (SI), non-hematopoietic cells were isolated as previously 
described (42). Skin non-hematopoietic cells were isolated from 
ear samples. Samples were harvested and the epidermis exposed 
by separating the external layers. Epidermis was incubated for 
45 min at 37°C with Liberase HL (0.5 mg/ml; Roche) and DNase I 
(1 U/mL; Invitrogen). After 45 min, non-hematopoietic cells were 
dissociated from the tissue by mechanical disruption, collected, 
washed in HBSS containing 10% FCS and recovered. At the 
end, non-hematopoietic cells were sort-purified by excluding all 
TaBle 2 | Parameters for histological analysis of colitis severity.
score epithelial 
hyperplasia 
and goblet 
depletion
leukocyte 
infiltration in 
the Lamina 
Propria
area 
affected
Markers 
of severe 
inflammation
0 None None/rare None None
1 Minimal Increase 1/3 Minimal
2 Mild Confluent 2/3 Increased
3 Marked Transmural All Confluent
The final score is obtained by the sum of individual scores. Markers of severe 
inflammation included ulceration and crypt abscesses.
TaBle 1 | Disease Activity Index (DAI) parameters.
score Weight loss stool consistency Bleeding
0 No loss Normal No blood
1 1–5% Mild soft Brown color
2 5–10% Very soft Reddish color
3 10–20% Diarrhea Bloody stool
4 >20% Gross bleeding
DAI is obtained by the sum of each individual score.
4
Cardoso et al. IL-10 Ameliorates DSS-Induced Colitis
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 400
CD45+ TER119+ cells (Figure S1A in Supplementary Material). 
Cell suspensions for all other organs were obtained by mechanical 
disruption.
Lamina propria leukocytes (LPLs) were prepared as previously 
described (43). Briefly, LPLs were harvested, dissociated and 
resuspended in Hank’s Balanced Solution (HBSS) supplemented 
with 1% fetal calf serum (FCS; Gibco). To isolate LPLs, the colon 
was flushed with phosphate-buffered saline (PBS; Gibco), opened 
and cut into 1 cm pieces. To eliminate epithelial cells these frag-
ments were incubated at 37°C in Ca- and Mg-free PBS containing 
10% FCS and 5.0 mM EDTA under strong agitation for 30 min. 
For LPL isolation, the remaining fragments were incubated in 
RPMI medium with Liberase TL (0.5 mg/ml; Roche) for 30 min 
at 37°C. To complete the digestion, the suspension was repeatedly 
passed through a 10 ml syringe for 5 min, filtered through a 40 μm 
cell strainer (BD Bioscience) and collected by centrifugation. The 
cell pellet was resuspended in 44% Percoll (GE Healthcare), laid 
over 67% Percoll, and centrifuged at 600 g for 20 min at 20°C. 
Cells at the interface were collected, washed in HBSS containing 
1% FCS and recovered.
antibodies
Antibodies were conjugated to fluorochromes (FITC, PE, PECy7, 
APC, APCCy7, Pacific Blue, and BV711) and were specific for the 
following mouse antigens: CD3 (145-2C11; Biolegend), CD11b 
(M1/70; Sony), CD11c (HL3; Biolegend), CD19 (6D5; Sony), 
CD45.2 (104; Biolegend), Ly6C (Hk1.4; eBioscience), Ly6G 
(RB6-8C5; BD Pharmingen), CD45 (30F11; Sony), and TER119 
(Ter119; BD Pharmingen).
cell sorting and Multiplex real Time-Pcr 
analysis
CD45− TER119− or CD45+ cells were sort-purified based on the 
expression of CD45 and TER119 using an Aria sorter (BD). Dead 
cells were eliminated by exclusion with propidium iodide (PI). 
mRNA from sorted cells was extracted using RNeasy Micro kit 
(Qiagen) and converted into cDNA by reverse transcription with 
PrimeScript RT Reagent kit (Takara, Clonetech). qRT-PCR was 
performed using Taqman primers (see Table S1 in Supplementary 
Material for references) and Taqman Universal Master Mix 
(Applied Biosystems). qRT-PCR reactions were performed on a 
ABI 7300 thermocycler (Applied Biosystems).
Lamina propria leukocytes were FACS-sort purified based on 
the expression of CD45.2, CD11b and Ly6C, using an Aria III 
sorter (BD). Cells expressing CD3, CD19, CD11c, and Ly6G were 
excluded. Dead cells were eliminated by exclusion with PI. CD45.2+ 
CD11b+ Ly6C+ cells were sorted directly into a mix of 9  µl of 
CellsDirect One-Step qRT-PCR kit (Life Technologies), contain-
ing a mixture of diluted primers (0.05× final concentration, see 
Table S1 in Supplementary Material for references). Preamplified 
cDNA (18 cycles), was obtained according to the manufacturer’s 
instructions and was diluted 1:5 in TE buffer (pH = 8; Ambion). 
The sample mixture was as follows: diluted cDNA (2.9 µl), Sample 
Loading Reagent (0.32 µl; Fluidigm), and Taqman Universal PCR 
Master Mix (3.5 µl; Applied Biosystems). The assay mixture was 
as follow: Assay Loafing Reagent (Fluidigm) and Taqman Mix. A 
48 × 48 Dynamic Array integrated fluidic circuit (IFC; Fluidigm) 
was primed with control line fluid, and the chip was loaded with 
assays and samples with and X IFC Controller (Fluidigm). The 
experiments were run on a BioMark HD (Fluidigm) for 40 cycles. 
Gene expression was normalized for Hprt and assessed by the 
2ΔCt method.
statistical analysis
Statistical analysis was performed with the Student’s t-test or two-
way analysis of variance as indicated in the figure legends. The 
analysis was performed with Prism Software (GraphPad). Graphs 
containing errors bars show means ± SEM. Statistical significance 
is represented as follows: *p < 0.05, **p < 0.01, and ***p < 0.001.
resUlTs
generation of a novel Mouse Model of 
il-10 Overexpression
To study the biological impact of IL-10 overexpression in dif-
ferent settings, we engineered a novel mouse model to allow 
for inducible IL-10 expression, the pMT-10 mouse (44). For 
this, a construct containing the IL-10 cDNA under the control 
of the inducible sheep MT promoter was introduced in the 
genome of wild-type BL/6 mice (Figure 1A). Whole genome 
sequencing revealed a single insertion of the transgene in chro-
mosome 10, between positions 78.813.656 and 78.992844  bp 
(Figure 1A). We estimated, by qRT-PCR, the number of cop-
ies of the transgene to be 50–100 (data not shown). The MT 
promoter is activated in the presence of 50 mM of Zn in the 
organism, administered in the drinking water. Kinetic analysis 
of IL-10 in the serum of pMT-10 mice fed with Zn-enriched 
water showed a rapid increase of circulating IL-10 (Figure 1B). 
Indeed, as soon as day 3 after IL-10 induction, the levels of 
this cytokine in the serum were very high (7–12  ng/ml) 
FigUre 2 | Dextran sulfate sodium (DSS)-induced pathology is ameliorated 
by preexposure to interleukin (IL)-10. (a) BL/6, pMT-10, and pMT-10.
IL-10Rα−/− mice were fed for 8 days with normal (BL/6-Zn, pMT-10-Zn, and 
pMT-10.IL-10Rα−/− Zn, respectively) or Zn-enriched (BL/6 + Zn, pMT-
10 + Zn, and pMT-10.IL-10Rα−/− + Zn) water, followed by 8 days of 3% DSS 
administration also in the drinking water. (B,F) Disease progression based on 
DAI parameters was registered every day for 8 days. Each point represents 
the mean ± SEM for three to five independent mice, in two independent 
experiments. (c) Colon length measurement at day 8 of DSS administration. 
(D) Representative H&E-stained sections of large bowel at 40× magnification 
(scale bar = 200 µm). (e) Colitis scores derived from evaluation of colon and 
cecum from either group. Each dot represents one independent animal; 
represented is also mean ± SEM. Data were analyzed with (B,F) two-way 
analysis of variance (Sidak’s multiple comparisons test) or (c,e) Student’s 
t-test. (B) # compare BL/6-Zn against BL/6 + Zn; ^ compare BL/6-Zn 
against pMT-10-Zn; • compare BL/6-Zn against pMT-10 + Zn; ∅ compare 
BL/6 + Zn against pMT-10-Zn; x compare BL/6 + Zn against pMT-10 + Zn,  
* compare pMT-10-Zn against pMT-10 + Zn. One symbol, p < 0.05; two 
symbols, p < 0.01; three symbols, p < 0.001.
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(Figure 1B). Moreover, suspending Zn administration led to 
a sharp drop in IL-10 in sera in only 24  h, to below detec-
tion levels in only 48 h (Figure 1B). As expected, circulating 
IL-10 was undetectable in pMT-10 mice fed with normal water 
(Figure  1B). Transcriptional analysis of different organs and 
cellular compartments of induced pMT-10 mice revealed that 
the expression of the exogenous IL-10 cDNA was restricted 
to CD45−TER119− cells from the SI, skin and, to a less extent, 
BM (Figure 1C). IL-10 induction was not detected in the other 
organs analyzed (liver, spleen, kidney, choroid plexus, lung, 
and colon) nor in hematopoietic cells isolated from the BM 
(Figure S1B in Supplementary Material). Thus, the pMT-10 
mouse model allows for timely controlled IL-10 overexpres-
sion in specific anatomic locations, accompanied by a strong 
increase of the levels of this cytokine in the serum.
Dss-induced colitis is ameliorated in 
il-10 Preexposed Mice
Despite the clear link between low levels of IL-10 and suscep-
tibility to colitis in human (45) as well as in mouse models (33, 
34), administration of IL-10 to treat this condition showed only 
limited effects (37). A possible reason may be the poor acces-
sibility of IL-10 to the site of inflammation. In this context, and 
in view of the high expression seen in the SI of induced mice, the 
pMT-10 mouse model offers an opportunity to further address 
the effects of IL-10 expression in the gut in the context of colitis. 
For this, we used the DSS experimental model, a highly reliable 
and reproducible way of causing UC-like symptoms in the mouse 
model by inducing acute inflammation with the recruitment of 
inflammatory cells (46).
We investigated the impact of IL-10 overexpression prior to 
DSS-induced colitis. For this, pMT-10 mice were induced to 
overexpress IL-10 for 8 days, before initiation of DSS adminis-
tration (Figure 2A). As controls, non-induced pMT-10 or BL6 
mice fed with control or Zn-enriched water were used. In our 
experimental setting, wild-type BL/6 mice started to show signs 
of disease from days 4 to 5 after administration of 3% DSS in 
the drinking water (Figure 2B). Control pMT-10 mice showed 
a progression of the DAI very similar to BL/6 mice (Figure 2B). 
As compared to pMT-10 or BL6 fed with control water, mice 
preconditioned with IL-10 showed significantly lower DAI 
after day 5 (Figure  2B) indicating that IL-10 conferred partial 
protection. Zn administration to BL6 mice prior to DSS, resulted 
in partial protection. Indeed, by day 7 of DSS administration, 
a significantly lower DAI was observed in BL/6 mice fed with 
Zn-enriched water as compared to BL6 control (Figure  2B). 
Nevertheless, the maximal protection was observed for pMT-10 
mice overexpressing IL-10, which suggests a synergistic effect 
of IL-10 and Zn in the amelioration of the disease (Figure 2B). 
The DAI encompasses three scores, one of which is the weight 
loss. Relatively to control animals, both pMT-10 and BL/6 mice 
fed with Zn prior to DSS administration showed less weight loss 
(Figure S2 in Supplementary Material). pMT-10 mice preexposed 
to IL-10 showed the least reduction in colon length as compared 
to all control groups (pMT-10 or BL/6 fed with control water, 
and BL/6 fed with Zn-enriched water – Figure 2C), in line with 
maximal protection being conferred by IL-10. Histologic analysis 
of the organ, comprising the analysis of inflammatory infiltrates, 
architectural distortion (crypt shortening and branching) and 
FigUre 3 | Ly6C+ cells preexposed to interleukin (IL)-10 reveal a less inflammatory profile upon DSS-induced colitis than those preexposed to Zn. (a) pMT-10 or 
BL/6 mice were fed with Zn-enriched water for 8 days, followed by 4 days of 3% DSS administration. (B) At the end of the DSS treatment, Lamina propria 
leukocytes (LPLs) were isolated and Ly6C+ cells sort-purified. Shown is the gating strategy for Ly6C+ cells purification. (c) Sort-purified Ly6C+ cells (n = 25 cells) 
were analyzed by qRT-PCR for a total of 22 genes using the BioMark HD system. Samples were normalized for Hprt expression. Represented is the expression 
heatmap compiling the genes which expression was detected in either mouse group. Each heatmap rectangle represents the mean of gene expression obtained for 
cells isolated from five independent mice. (D) The frequency of the different leukocyte subsets was determined upon staining of LPLs for Ly6C+ cell sorting. Each 
dot represents one independent animal; represented is also mean ± SEM. Data were analyzed with Student’s t-test, *p < 0.05.
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ulceration, showed an improvement in pMT-10 mice preexposed 
to IL-10 as compared to BL/6 preexposed to Zn (Figures 2D,E). 
However, despite a reduction in the histological score of some 
pMT-10 mice preexposed to IL-10, the overall group did not 
reach statistical significance when compared to the other control 
groups (Figures 2D,E).
Thus, our data showed that IL-10 overexpression prior to 
intestinal insult afforded a significant degree of protection 
from DSS-induced colitis. Additionally, our data also suggest 
a synergistic effect of IL-10 and Zn in the amelioration of the 
disease. To investigate this issue, we repeated the experiment 
using pMT-10 mice crossed with IL-10Rα−/− mice. Since pMT-
10.IL-10Rα−/− double mutant mice are unresponsive to IL-10, 
the effects observed would only be due to Zn administration. In 
these mice, we observed an accelerated disease progression upon 
DSS administration, with an elevated DAI score as early as day 
3, in line with the known role of IL-10 in controlling the disease 
(Figure 2F). In these mice, Zn administration did not confer pro-
tection against DSS-induced colitis (Figure 2F). Taken together, 
our findings support the notion that the protection conferred by 
Zn requires IL-10 signaling.
Preexposure to il-10 Promotes a More 
controlled inflammatory response
Previous studies have shown that monocytes and macrophages 
are the major effector subsets of colonic inflammation (34, 47). 
Mice with macrophage-specific IL-10R deficiency develop a 
spontaneous colitic profile, emphasizing the importance of IL-10 
in regulating the macrophage response to prevent uncontrolled 
inflammation (34). Thus, we next investigated whether IL-10 
ameliorated DSS-induced colitis by restricting the monocyte/
macrophage response. Considering that Zn administration also 
improved the outcome of DSS-induced colitis in BL/6 mice, we 
compared the transcriptional profile of monocytes/macrophages 
from BL/6 or pMT-10 mice preexposed to Zn and subjected to 
DSS administration for 4 days. We chose this time point, since 
signs of colitis induced by DSS in both BL/6 and pMT-10 mice 
only become obvious after day 4 of DSS administration. Thus, 
BL/6 and pMT-10 mice were fed with Zn-enriched water for 
8 days and then received DSS for 4 days (Figure 3A). At this time 
point, Ly6C+ cells from each mouse from the different groups 
were FACS purified (Figure 3B). Expression of 22 genes (Table 
S1 in Supplementary Material) associated with the uncontrolled 
FigUre 4 | The interleukin-10 protection conferred against DSS-induced colitis is not long lasting. (a) pMT-10 mice were fed with control (pMT-10-Zn) or 
Zn-enriched (pMT-10 + Zn) water for 8 days, followed by a 7- or 21-day resting period where only normal water was available, and by 8 days of 3% DSS.  
(B) Disease progression based on Disease Activity Index (DAI) parameters was registered every day for 8 days. (c) Colon length measurement at day 8 of DSS 
administration. (D) Representative H&E-stained sections of large bowel at 40× magnification (scale bar = 200 µm). (e) Colitis scores derived from evaluation of colon 
and cecum from both groups. Each dot represents one independent animal, in two independent experiments; represented is also mean ± SEM. Data were analyzed 
with (B) two-way analysis of variance (Sidak’s multiple comparisons test) or (c,e) Student’s t-test.
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immune response developed in IBD were analyzed by multi-
plex RT-PCR. All samples, from both groups, expressed three 
house-keeping genes (Hprt, Actb, and Gapdh). Of the 22 genes 
analyzed, we failed to detect expression of 9 (Il4, Il9, Il12α, Il12β, 
Il13, Il17, Il23, Ifnγ, and Cx3cl1) in Ly6C+ cells isolated from the 
lamina propria in both groups. We detected expression of the 10 
remaining genes in Ly6C+ cells, in Zn-fed BL/6 and pMT-10 mice 
after DSS administration (Figure 3C), but no expression in the 
absence of insult (data not shown). Thus, Ly6C+ cells alter their 
expression profile in response to DSS insult. Most interestingly, 
on day 4 post-DSS administration, Ly6C+ cells isolated from 
induced pMT-10 mice presented an overall less inflammatory 
profile than those isolated from BL/6 mice (Figure 3C). In the 
case of Tnfα and Cd86, the differences observed between the two 
mouse groups were statistically significant (Figure  3C). In all, 
these findings suggest that exposure to IL-10 before DSS induc-
tion acts by preventing an inflammatory profile in Ly6C+ cells. 
Of note, the frequency of inflammatory macrophages recruited 
to the inflamed gut was similar between the two groups, and the 
same was true for CD3 T cells and CD19 B cells, showing that 
IL-10 overexpression does not impact the recruitment of immune 
cells to the gut (Figure 3D).
il-10 Protection against Dss-induced 
colitis is not long lasting
In our mouse model, IL-10 is also overexpressed in the BM and 
is found at high levels in the serum, possibly creating an anti-
inflammatory environment that could precondition de novo 
generated or circulating monocytes. In this setting, the circulat-
ing monocytes could thus be educated to be less responsive once 
recruited to the colon during DSS-induced colitis. To study this 
possibility, we combined a period of IL-10 overexpression with 
a resting period of 7 or 21  days prior to DSS administration 
(Figure 4A). As shown in Figure 1B, the levels of IL-10 return 
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to basal ones as soon as 24  h after the zinc administration is 
suspended. Thus, after a 7-day rest, the circulating levels of IL-10 
are normalized. Furthermore, we chose the 21 days time-point, 
because previous reports showing that resident intestinal mac-
rophages have a life span of approximately 3 weeks (48). After 
7-day rest period, the protection in DAI afforded by previous 
IL-10 exposure was partly lost (Figure 4B), being less pronounced 
than when no resting was performed and only observed at later 
time-points. After the 21-day resting period, the protection in 
DAI of pMT-10 previously overexpressing IL-10 was completely 
ablated (Figure 4B). Furthermore, independently of the resting 
period, no differences were observed between the experimental 
groups in what concerned colon length (Figure 4C) or histology 
(Figures  4D,E). Thus, we conclude that IL-10 overexpression, 
over a period of 8 days, does not confer long-lasting protection 
against intestinal inflammation.
DiscUssiOn
Despite the fact that IBD is a treatable condition, there are many 
limitations to the therapeutic approaches currently available 
(5). Major obstacles in this context are the heterogeneity of the 
disease, which implies that dosage and schedule may differ across 
disease conditions, and the requirement of a localized action of 
the therapeutic agent. In view of the strong immune component 
associated with disease development, it is not surprising that 
therapeutic manipulations of the immune response have been 
widely sought approaches to tackle IBD. Indeed, a commonly 
used therapy for IBD is the administration of anti-tumor necrosis 
factor alpha (TNF-α) antibodies (49). However, in line with the 
above mentioned limitations, up to one-third of IBD patients do 
not respond to this therapy, and those who respond eventually 
develop some degree of intolerance to the medication (50). In 
this context, several animal models of IBD, both spontaneous 
and experimentally induced (such as DSS), were developed to 
investigate the role of various factors on the pathogenesis of the 
disease and to evaluate the different therapeutic options. A mol-
ecule that has been widely studied in the context of IBD is IL-10. 
This cytokine keeps intestinal inflammation in check by exerting 
a direct effect on monocyte/macrophage populations (34). Thus, 
it is not surprising that IL-10-based therapies have been tested in 
IBD. However, both in human (51–54) and mouse models (38), 
administration of IL-10 did not significantly improve intestinal 
inflammation, perhaps in part due to the fact that administered 
IL-10 did not reach the inflamed tissue.
In this study, we report a novel transgenic mouse model of 
inducible IL-10 overexpression, the pMT-10 mice, in which 
high IL-10 transcription is observed in the intestine, skin and 
BM. Upon induction of the transgene, high levels of IL-10 are 
detected also in the serum. Taking advantage of this novel mouse 
model, we investigated the dynamics of IL-10 afforded protection 
during DSS-induced colitis. We found that induction of IL-10 
prior to DSS administration impacted the progression of colitis. 
We show that a short period of IL-10 overexpression before the 
induction of colitis ameliorated the disease outcome, despite the 
presence of CD11b+ Ly6C+ cells in the gut, previously associated 
with the development of detrimental inflammation. However, 
in comparison to control animals that do not overexpress IL-10, 
Ly6C cells isolated from the lamina propria of colitic pMT-10 
mice showed a decreased inflammatory profile. Thus, we hypoth-
esize that IL-10 overexpression impairs the response of these cells 
to the insult, reaffirming both the critical role of these cells on 
intestinal inflammation (47) and that of IL-10 in regulating their 
inflammatory responses (34). In line with a previously described 
protective role for Zn in the context of intestinal inflammation 
(55, 56), we show some effect of Zn in reducing the severity of 
colitis, which occurred both later and to a lower extent than that 
observed for the combined condition Zn + IL-10. In addition, the 
protective effect of Zn failed to overcome the exacerbated colitis 
observed in mice that did not respond to endogenous IL-10. The 
mechanistic bases underlying the protection conferred by Zn 
alone remain unknown. One possibility is that Zn may contribute 
to diminish the amount of free radical species generated during 
acute colitis which contribute to protein, DNA chain and lipid 
damage (57). In any case, as IBD patients often present a Zn defi-
ciency and respond well to Zn supplementation therapy (58), the 
exploitation of combined IL-10 and Zn therapies may be worth 
considering. In line with this, the benefits of combined Zn and 
anti-TNF therapy were previously described (55).
The pMT-10 mouse model allows for local, as well as systemic, 
IL-10 overexpression. The fact that we detected increased tran-
scription of the IL-10 transgene in the BM and elevated levels of 
seric IL-10 led us to hypothesize that preexposure to IL-10 might 
induce long-lasting transcriptional changes in circulating mono-
cytes, for example through epigenetic imprinting. If this were the 
case, we might be able to educate these cells to gain long-lasting 
tolerance to DSS-induced colitis. Our data obtained after a 1- or 
3-week rest post-IL-10 exposure show that recent IL-10 exposure 
is required for maximal protection. Thus, the protective effects of 
IL-10 were not sustained over time, implying that IL-10 presence 
at the time of insult is necessary to prevent colitis. Therefore, 
inducing IL-10 expression in our mouse model at the beginning 
of disease would be of interest. Unfortunately, we were unable 
to explore this possibility because the Zn necessary to activate 
the transgene precipitates in the presence of DSS, when both are 
provided in the drinking water. In addition, we were unable to 
induce high levels of IL-10 expression in the serum of mice fed 
with a Zn-enriched diet and ethical issues prevented us from 
attempting to induce sustained high levels of IL-10 by frequent 
gavage or i.p. injections of Zn-containing preparations.
In conclusion, we herein present a novel mouse model of 
inducible IL-10 overexpression. We also show the potential of this 
model for the study of the IL-10 biology in the specific setting of 
DSS-induced colitis. Our data further support the protective role 
for IL-10 in intestinal inflammation, showing that this cytokine 
delays disease progression even when delivered before DSS 
administration. However, the effect is not long-lasting, which 
calls for alternative approaches to prevent IBD.
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